CU23636A1 - Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) - Google Patents
Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf)Info
- Publication number
- CU23636A1 CU23636A1 CU20060208A CU20060208A CU23636A1 CU 23636 A1 CU23636 A1 CU 23636A1 CU 20060208 A CU20060208 A CU 20060208A CU 20060208 A CU20060208 A CU 20060208A CU 23636 A1 CU23636 A1 CU 23636A1
- Authority
- CU
- Cuba
- Prior art keywords
- vegf
- molecules
- growth factor
- vitro
- endotelium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
Moléculas polipeptídicas recombinantes relacionadas con anticuerpos, que reconocen específicamente el Factor de Crecimiento de Endotelio Vascular-A (VEGF-A) humano, e interfieren con sus efectos estimulatorios in vitro, y proangiogénicos in vivo. Dichas moléculas polipeptídicas recombinantes son capaces de afectar la proliferación de células endoteliales humanas in vitro, la angiogénesis subcutánea en ratones inducida por tapones de Matrigel que contienen VEGF-A, y el crecimiento de tumores humanos trasplantados a ratones desnudos. Varias de estas moléculas previenen la neovascularización coroidea en un modelo experimental en primates no humanos. Estas moléculas pueden emplearse para inmunoterapia pasiva de entidades patológicas cuyo curso se asocia al aumento de la vasculatura, tales como la degeneración macular asociada a la edad (variante húmeda), el cáncer y sus metástasis, los glaucomas neovasculares, la retinopatía diabética y del recién nacido, los procesos inflamatorios agudos y crónicos, enfermedades infecciosas, enfermedades autoinmunes, el rechazo al trasplante de órganos, los hemangiomas y los angiofibromas, entre otros.
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20060208A CU23636A1 (es) | 2006-11-01 | 2006-11-01 | Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) |
BRPI0717971-5A2A BRPI0717971A2 (pt) | 2006-11-01 | 2007-10-30 | Anticorpos recombinantes contra o fator de crescimento endotelial vascular (vegf) |
MX2009004765A MX2009004765A (es) | 2006-11-01 | 2007-10-30 | Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf). |
RU2009120536/10A RU2009120536A (ru) | 2006-11-01 | 2007-10-30 | Рекомбинантные антитела против васкулярного эндотелиального фактора роста (vegf) |
CNA2007800437331A CN101573379A (zh) | 2006-11-01 | 2007-10-30 | 针对血管内皮生长因子(vegf)的重组抗体 |
AU2007315484A AU2007315484A1 (en) | 2006-11-01 | 2007-10-30 | Recombinant antibodies against vascular endothelial growth factor (VEGF) |
EP07817383A EP2093236A1 (en) | 2006-11-01 | 2007-10-30 | Recombinant antibodies against vascular endothelial growth factor (vegf) |
JP2009534978A JP2010508033A (ja) | 2006-11-01 | 2007-10-30 | 血管内皮増殖因子(vegf)に対する組換え抗体 |
PCT/CU2007/000019 WO2008052489A1 (es) | 2006-11-01 | 2007-10-30 | Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) |
US12/447,711 US20100151566A1 (en) | 2006-11-01 | 2007-10-30 | Recombinant antibodies against the vascular endothelial growth factor (vegf) |
KR1020097011229A KR20090078363A (ko) | 2006-11-01 | 2007-10-30 | 혈관 내피 성장 인자(vegf)에 대한 재조합 항체 |
CA002667594A CA2667594A1 (en) | 2006-11-01 | 2007-10-30 | Recombinant antibodies against vascular endothelial growth factor (vegf) |
ARP070104873A AR063448A1 (es) | 2006-11-01 | 2007-11-01 | Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) |
ZA200903017A ZA200903017B (en) | 2006-11-01 | 2009-04-30 | Recombinant antibodies against vascular endothelial growth factor (VEGF) |
CO09056360A CO6341480A2 (es) | 2006-11-01 | 2009-06-01 | Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20060208A CU23636A1 (es) | 2006-11-01 | 2006-11-01 | Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) |
Publications (1)
Publication Number | Publication Date |
---|---|
CU23636A1 true CU23636A1 (es) | 2011-03-21 |
Family
ID=39148565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU20060208A CU23636A1 (es) | 2006-11-01 | 2006-11-01 | Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) |
Country Status (15)
Country | Link |
---|---|
US (1) | US20100151566A1 (es) |
EP (1) | EP2093236A1 (es) |
JP (1) | JP2010508033A (es) |
KR (1) | KR20090078363A (es) |
CN (1) | CN101573379A (es) |
AR (1) | AR063448A1 (es) |
AU (1) | AU2007315484A1 (es) |
BR (1) | BRPI0717971A2 (es) |
CA (1) | CA2667594A1 (es) |
CO (1) | CO6341480A2 (es) |
CU (1) | CU23636A1 (es) |
MX (1) | MX2009004765A (es) |
RU (1) | RU2009120536A (es) |
WO (1) | WO2008052489A1 (es) |
ZA (1) | ZA200903017B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101093717B1 (ko) * | 2008-11-26 | 2011-12-19 | 한국생명공학연구원 | Vegf―특이적인 인간항체 |
CU23895B1 (es) * | 2010-12-28 | 2013-05-31 | Biorec Sa | Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagénesis de regiones variables |
CN103012588A (zh) * | 2011-09-23 | 2013-04-03 | 武汉吉天朋生物科技发展有限公司 | 利用具有中和VEGFA生物学活性的McAb应用于肿瘤的靶向治疗 |
CN104073502B (zh) * | 2013-03-26 | 2016-08-24 | 华东师范大学 | 人脑钠肽的中和性基因工程抗体3c1及其制备方法和应用 |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
CL2014002941A1 (es) * | 2014-10-30 | 2015-04-06 | Univ Concepcion | Moléculas polipeptídicas contra el factor de crecimiento del endotelio vascular (vegf) |
BR112018013407A2 (pt) | 2015-12-30 | 2018-12-18 | Kodiak Sciences Inc | anticorpos e conjugados dos mesmos |
EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | METHOD FOR TREATING AN EYE DISORDER |
CU20210101A7 (es) | 2021-12-15 | 2023-07-12 | Ct Ingenieria Genetica Biotecnologia | Polipéptidos que se unen a factores de crecimiento proangiogénicos |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
JPH05184352A (ja) | 1990-01-16 | 1993-07-27 | Centro De Ing Genetica Y Biotecnol | ピヒア パストリス(Pichia pastoris)酵母中での異種遺伝子の発現方法、発現ベクターおよび形質転換微生物 |
EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
US5730977A (en) | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2006
- 2006-11-01 CU CU20060208A patent/CU23636A1/es unknown
-
2007
- 2007-10-30 CN CNA2007800437331A patent/CN101573379A/zh active Pending
- 2007-10-30 KR KR1020097011229A patent/KR20090078363A/ko not_active Application Discontinuation
- 2007-10-30 RU RU2009120536/10A patent/RU2009120536A/ru not_active Application Discontinuation
- 2007-10-30 AU AU2007315484A patent/AU2007315484A1/en not_active Abandoned
- 2007-10-30 EP EP07817383A patent/EP2093236A1/en not_active Withdrawn
- 2007-10-30 CA CA002667594A patent/CA2667594A1/en not_active Abandoned
- 2007-10-30 US US12/447,711 patent/US20100151566A1/en not_active Abandoned
- 2007-10-30 BR BRPI0717971-5A2A patent/BRPI0717971A2/pt not_active IP Right Cessation
- 2007-10-30 MX MX2009004765A patent/MX2009004765A/es unknown
- 2007-10-30 JP JP2009534978A patent/JP2010508033A/ja not_active Abandoned
- 2007-10-30 WO PCT/CU2007/000019 patent/WO2008052489A1/es active Search and Examination
- 2007-11-01 AR ARP070104873A patent/AR063448A1/es not_active Application Discontinuation
-
2009
- 2009-04-30 ZA ZA200903017A patent/ZA200903017B/xx unknown
- 2009-06-01 CO CO09056360A patent/CO6341480A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN101573379A (zh) | 2009-11-04 |
KR20090078363A (ko) | 2009-07-17 |
BRPI0717971A2 (pt) | 2013-11-12 |
CO6341480A2 (es) | 2011-11-21 |
MX2009004765A (es) | 2009-06-05 |
RU2009120536A (ru) | 2010-12-10 |
WO2008052489A8 (es) | 2009-07-23 |
JP2010508033A (ja) | 2010-03-18 |
WO2008052489A1 (es) | 2008-05-08 |
AU2007315484A1 (en) | 2008-05-08 |
CA2667594A1 (en) | 2008-05-08 |
AR063448A1 (es) | 2009-01-28 |
US20100151566A1 (en) | 2010-06-17 |
EP2093236A1 (en) | 2009-08-26 |
ZA200903017B (en) | 2010-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU23636A1 (es) | Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) | |
Hu et al. | Exosomes secreted by human-induced pluripotent stem cell-derived mesenchymal stem cells attenuate limb ischemia by promoting angiogenesis in mice | |
Gong et al. | Mesenchymal stem cells stimulate intestinal stem cells to repair radiation-induced intestinal injury | |
Guan et al. | Mesenchymal stem cells in the tumor microenvironment | |
Hajizadeh-Saffar et al. | Inducible VEGF expression by human embryonic stem cell-derived mesenchymal stromal cells reduces the minimal islet mass required to reverse diabetes | |
JP2018502115A (ja) | ナチュラルキラー細胞及びその使用 | |
UY35258A (es) | ANTICUERPOS ANTI-PDGFR-beta Y USOS DE LOS MISMOS | |
CR20140047A (es) | Dominios variables singulares anti-vgf fusionados con dominios de fc | |
Lee et al. | Differential migration of mesenchymal stem cells to ischemic regions after middle cerebral artery occlusion in rats | |
AR068997A1 (es) | Anticuerpos contra el vegf completamente humano y sus metodos de uso | |
GT201600007A (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
AR039285A1 (es) | Inmunoterapia activa antiangiogenica composicion vacunal | |
ECSP20082338A (es) | Receptores del factor de crecimiento quimérico | |
EA201391154A3 (ru) | Способы и композиции для нацеливания на адипоциты у млекопитающих | |
FI3347027T3 (fi) | Neo-saarekkeita käsittäen kanta- ja saarekesoluja ja diabetes mellituksen hoito niillä | |
Dzobo et al. | Wharton’s jelly-derived mesenchymal stromal cells and fibroblast-derived extracellular matrix synergistically activate apoptosis in a p21-dependent mechanism in WHCO1 and MDA MB 231 cancer cells in vitro | |
BR112015009229A2 (pt) | composição tendo como alvo a expressão de genes para plaquetas, célula tronco hematopoiética, uso da referida célula tronco e método in vitro ou ex vivo para gerar uma célula tronco modificada | |
MX2020005849A (es) | Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos. | |
CO2020006855A2 (es) | Composiciones y métodos para el agotamiento de células cd2+ | |
AR113562A1 (es) | Método para inhibir la angiogénesis | |
AR084618A1 (es) | Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagenesis de regiones variables | |
Van Pham et al. | Production of endothelial progenitor cells from skin fibroblasts by direct reprogramming for clinical usages | |
Stachon et al. | Impact of crosslinking/riboflavin-UVA-photodynamic inactivation on viability, apoptosis and activation of human keratocytes in vitro | |
Notara et al. | Short-term ultraviolet a irradiation leads to dysfunction of the limbal niche cells and an antilymphangiogenic and anti-inflammatory micromilieu | |
BR112014026606A2 (pt) | métodos para a indução de células t reguladoras específicas de antígeno |